Intraoperative Radiation Therapy

Intraoperative radiation therapy (IORT) delivers radiation during surgery, allowing clinicians to treat a defined tumor bed while surrounding organs can be displaced or shielded. Its clinical role is most relevant where surgery and radiation planning must be closely coordinated, including selected breast, colorectal, pancreatic, sarcoma, gynecologic, and recurrent cancer cases. Adoption depends on evidence quality, multidisciplinary expertise, operating-room integration, safety protocols, reimbursement, and access to specialized equipment.

IORT is moving from an equipment-centered intervention toward a coordinated care pathway involving surgeons, radiation oncologists, medical physicists, anesthesiologists, radiographers, and hospital administrators. Hybrid operating environments, image guidance, treatment planning software, and improved radiation-safety workflows are supporting more precise intraoperative decision-making. At the same time, institutions increasingly evaluate IORT against alternatives such as postoperative external-beam radiation, brachytherapy, and systemic treatment, with emphasis on patient selection, toxicity, local control, workflow disruption, and total care requirements.

Artificial intelligence can support IORT through automated image segmentation, delineation of tumor beds and organs at risk, treatment-plan comparison, dose verification, and identification of patients most likely to benefit. Predictive models may also help integrate pathology, imaging, operative findings, and prior treatment history into individualized decisions. However, clinical deployment requires representative datasets, prospective validation, explainability, cybersecurity, human oversight, and controls against algorithmic bias. AI should augment multidisciplinary judgment rather than replace radiation-safety review or clinician accountability.

North America benefits from advanced oncology infrastructure, specialized centers, and established multidisciplinary practice, although capital requirements, reimbursement variation, and operating-room coordination influence adoption. Europe combines strong cancer networks and clinical research capacity with differing national health-technology assessments and procurement processes. Asia-Pacific presents substantial variation: Japan, Australia, South Korea, China, India, and Southeast Asian systems differ in technology access, specialist availability, and referral concentration. Latin America is shaped by uneven access to oncology services, urban concentration, and public-private differences. The Middle East is developing specialist cancer capacity through tertiary hubs and cross-border referral networks, while Africa faces pronounced shortages of equipment, trained personnel, and radiotherapy infrastructure, making regional centers and partnership models important.

ASEAN members show diverse levels of oncology infrastructure, with adoption most feasible through hub-and-spoke referral systems, workforce development, and shared clinical protocols. BRICS countries combine major academic centers with significant internal disparities in access, reimbursement, and technology deployment. The European Union benefits from collaborative research and cross-border policy dialogue, but national implementation and reimbursement remain distinct. G7 health systems generally possess strong research, surgical, and radiation capabilities, while still facing workforce pressure and cost-effectiveness scrutiny. GCC states are expanding tertiary oncology capacity and may support centralized, technology-enabled services. NATO members span mature and developing health systems, making interoperability, emergency preparedness, and resilient supply chains relevant to specialized oncology delivery.

Australia and Canada rely on concentrated specialist networks and coordinated referral pathways, with geography affecting access. The United States has extensive academic oncology capability but substantial variation in coverage, institutional resources, and evidence requirements. Brazil and Mexico face disparities between major urban centers and underserved regions. China and India combine rapidly advancing tertiary capabilities with wide geographic and institutional variation. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established oncology and radiation expertise, while adoption is influenced by national guidelines, hospital procurement, staffing, and reimbursement frameworks. Russia’s implementation environment is shaped by centralized specialist capacity, regional access differences, and broader healthcare-system constraints.

Industry leaders should prioritize indication-specific clinical evidence, transparent patient-selection criteria, and prospective outcomes collection covering local control, toxicity, quality of life, and workflow impact. Hospitals should establish multidisciplinary governance, standardized radiation-safety procedures, competency-based training, and contingency plans for equipment or staffing interruptions. Technology developers should focus on interoperability with imaging, oncology information, and operating-room systems; usability; dose verification; and secure data architecture. Health systems can improve access through referral networks, shared specialist services, and structured evaluation frameworks that compare IORT with clinically appropriate alternatives rather than treating equipment acquisition as the primary objective.

This executive summary uses the defined market scope of intraoperative radiation therapy and synthesizes established clinical, operational, technological, policy, and geographic considerations. The assessment framework examines treatment applications, multidisciplinary workflow, enabling technologies, infrastructure, workforce, reimbursement, regulation, patient access, and regional variation. Qualitative conclusions should be validated against peer-reviewed clinical studies, professional guidelines, regulatory documentation, institutional outcomes, and health-system procurement evidence. No market estimates, market shares, forecasts, or company-specific claims are used.

Intraoperative radiation therapy has a focused role within multidisciplinary cancer care rather than a universal replacement for postoperative radiation approaches. Its future relevance will depend on selecting patients with clear clinical rationale, demonstrating durable outcomes, integrating treatment safely into surgical workflows, and expanding specialist capability beyond a small number of centers. AI, digital planning, and coordinated referral models can improve consistency and access, but their value will depend on validation, governance, and alignment with local health-system realities.